These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31471269)

  • 41. Emerging Role of Combination Immunotherapy in the First-line Treatment of Advanced Renal Cell Carcinoma: A Review.
    George S; Rini BI; Hammers HJ
    JAMA Oncol; 2019 Mar; 5(3):411-421. PubMed ID: 30476955
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Type 1 diabetes in a melanoma patient treated with ipilimumab after nivolumab.
    Omodaka T; Kiniwa Y; Sato Y; Suwa M; Sato M; Yamaguchi T; Sato A; Miyake T; Okuyama R
    J Dermatol; 2018 Oct; 45(10):e289-e290. PubMed ID: 29667767
    [No Abstract]   [Full Text] [Related]  

  • 43. Nivolumab efficacy in leptomeningeal metastasis of renal cell carcinoma: a case report.
    Bonomi L; Bettini AC; Arnoldi E; Chirco A; Ghilardi L; Manara O; Roscigno M; Da Pozzo LF; Tondini CA
    Tumori; 2020 Dec; 106(6):NP76-NP78. PubMed ID: 32041500
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Newly developing brain metastases during nivolumab therapy for metastatic renal cell carcinoma: A case series in two Japanese institutions.
    Ishihara H; Kondo T; Takagi T; Yoshida K; Okumi M; Tanabe K
    Int J Urol; 2019 Aug; 26(8):849-850. PubMed ID: 31115103
    [No Abstract]   [Full Text] [Related]  

  • 45. Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution.
    Sukari A; Nagasaka M; Alhasan R; Patel D; Wozniak A; Ramchandren R; Vaishampayan U; Weise A; Flaherty L; Jang H; Kim S; Gadgeel S
    Anticancer Res; 2019 Feb; 39(2):781-790. PubMed ID: 30711957
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
    Yilmaz M
    J Oncol Pharm Pract; 2020 Jan; 26(1):236-239. PubMed ID: 30955467
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature.
    Hasegawa T; Ozaki Y; Inoue T; Watanabe Y; Fukuhara M; Yamaura T; Muto S; Okabe N; Higuchi M; Shio Y; Suzuki H
    J Med Case Rep; 2019 Oct; 13(1):316. PubMed ID: 31647029
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bullous lichen planus and anti-programmed cell death-1 therapy: Case report and literature review.
    de Lorenzi C; André R; Vuilleumier A; Kaya G; Abosaleh M
    Ann Dermatol Venereol; 2020 Mar; 147(3):221-227. PubMed ID: 31982173
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prolonged survival of a patient with papillary renal cell carcinoma and brain metastases using pazopanib.
    Jacobs C; Kim DW; Straka C; Timmerman RD; Brugarolas J
    J Clin Oncol; 2013 Mar; 31(7):e114-7. PubMed ID: 23319695
    [No Abstract]   [Full Text] [Related]  

  • 50. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.
    Yamauchi I; Yasoda A; Matsumoto S; Sakamori Y; Kim YH; Nomura M; Otsuka A; Yamasaki T; Saito R; Kitamura M; Kitawaki T; Hishizawa M; Kawaguchi-Sakita N; Fujii T; Taura D; Sone M; Inagaki N
    PLoS One; 2019; 14(5):e0216954. PubMed ID: 31086392
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Case of acute-onset type 1 diabetes induced by long-term immunotherapy with nivolumab in a patient with mucosal melanoma.
    Maekawa T; Okada K; Okada H; Kado S; Kamiya K; Komine M; Murata S; Oka K; Ishibashi S; Ohtsuki M
    J Dermatol; 2019 Dec; 46(12):e463-e464. PubMed ID: 31436330
    [No Abstract]   [Full Text] [Related]  

  • 52. Nivolumab-associated digital small-vessel vasculitis in a patient with an advanced renal cell carcinoma.
    Franco F; Méndez M; Gutierrez L; Sanz J; Calvo V; Provencio M
    Immunotherapy; 2019 Apr; 11(5):379-384. PubMed ID: 30786844
    [TBL] [Abstract][Full Text] [Related]  

  • 53. No recurrence of nivolumab-induced idiopathic thrombocytopenic purpura in a metastatic melanoma patient switched to ipilimumab.
    Takimoto R; Otsuka A; Kaku Y; Honda T; Kabashima K
    Eur J Dermatol; 2018 Feb; 28(1):84-85. PubMed ID: 29400292
    [No Abstract]   [Full Text] [Related]  

  • 54. Case Report of Akathisia in a Patient With Metastatic Renal Cell Carcinoma on Nivolumab.
    Ho SX; Gass CE; Ruark JM
    J Acad Consult Liaison Psychiatry; 2021; 62(1):119-122. PubMed ID: 33008604
    [No Abstract]   [Full Text] [Related]  

  • 55. Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025.
    Escudier B; Motzer RJ; Sharma P; Wagstaff J; Plimack ER; Hammers HJ; Donskov F; Gurney H; Sosman JA; Zalewski PG; Harmenberg U; McDermott DF; Choueiri TK; Richardet M; Tomita Y; Ravaud A; Doan J; Zhao H; Hardy H; George S
    Eur Urol; 2017 Sep; 72(3):368-376. PubMed ID: 28410865
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Concurrent radiotherapy and nivolumab in metachronous metastatic primary adenosquamous-cell carcinoma of the prostate.
    Eze C; Manapov F; Gratzke C; Schmidt-Hegemann NS; Jung A; Kirchner T; Heinemann V; Stief CG; Belka C; Boeck S
    Eur J Cancer; 2018 May; 95():109-111. PubMed ID: 29477368
    [No Abstract]   [Full Text] [Related]  

  • 57. Immune Checkpoint Inhibitors and Myasthenic Syndromes: A Case Report of a Metastatic Renal Cell Carcinoma Patient Treated With Nivolumab.
    Cortellini A; Napoleoni L; Cimini N; Parisi A; Pavese F; DʼOrazio C; Verna L; Porzio G; Ficorella C
    J Clin Neuromuscul Dis; 2018 Dec; 20(2):99-100. PubMed ID: 30439756
    [No Abstract]   [Full Text] [Related]  

  • 58. Efficacy and toxicity of ipilimumab used after nivolumab in patients with melanoma.
    Sato M; Uhara H; Koga H; Okuyama R
    J Dermatol; 2018 Oct; 45(10):e287-e289. PubMed ID: 29655228
    [No Abstract]   [Full Text] [Related]  

  • 59. Efficacy and safety profile of nivolumab for Japanese patients with metastatic renal cell cancer.
    Fujiwara R; Inamura K; Yuasa T; Numao N; Yamamoto S; Masuda H; Kawauchi A; Takeuchi K; Yonese J
    Int J Clin Oncol; 2020 Jan; 25(1):151-157. PubMed ID: 31522314
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Isolated Adrenocorticotropic Hormone Deficiency in Melanoma Patients Treated with Nivolumab.
    Kitano S; Tatsuno K; Ishibe J; Shimauchi T; Fujiyama T; Ito T; Ogawa N; Tokura Y
    Acta Derm Venereol; 2018 Jul; 98(7):704-705. PubMed ID: 29405244
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.